Philip Morris International

Philip Morris International is a leading global tobacco and smoke-free products company, operating in over 180 markets outside the United States. It was spun off from Altria in 2008, inheriting a vast international portfolio of iconic cigarette brands. The company has increasingly focused on developing and commercializing smoke-free alternatives, aiming to transition away from traditional cigarettes.

History

The company's origins are tied to the 1847 founding of a London tobacconist by Philip Morris. Its modern international expansion accelerated under the stewardship of its former parent, Altria (formerly Philip Morris Companies Inc.), particularly after World War II. A pivotal moment came in 2008 when it was formally separated from Altria, allowing it to pursue independent global strategies without the constraints of U.S. litigation and regulations. Since then, it has made significant investments in research and development, notably acquiring expertise in aerosol technology through its purchase of a stake in JUUL Labs and developing its own platform, which led to the launch of its flagship heated tobacco product, IQOS.

Products

The company's portfolio is dominated by its flagship cigarette brand, Marlboro, one of the world's most valuable consumer brands. Other major international cigarette brands include L&M, Chesterfield, and Philip Morris. Its primary smoke-free product is IQOS, a heated tobacco system that heats rather than burns tobacco. The company also markets VEEV, a nicotine-containing e-vapor product, and has a license agreement for the U.S. commercialization of IQOS through Altria. These products are developed at major research facilities like the PMI Research & Development center in Neuchâtel, Switzerland.

Business operations

Headquartered in Stamford, Connecticut, the company manages a complex global supply chain with manufacturing facilities worldwide, including major plants in Europe and Asia. Its commercial operations are divided into six geographical segments: the European Union, Eastern Europe, the Middle East & Africa, South & Southeast Asia, East Asia & Australia, and Latin America & Canada. A significant portion of its revenue is generated in key markets like Japan, Germany, and Italy. The company engages in extensive agricultural sourcing, often working directly with leaf growers in countries such as Brazil, Malawi, and Turkey.

Controversies and litigation

The company has been involved in numerous legal and public health controversies, largely inherited from the wider tobacco industry's history. It has faced major litigation worldwide, including class-action lawsuits and cases brought by governments, such as those led by the U.S. Department of Justice. The World Health Organization has been a persistent critic of the industry's marketing practices. More recently, its promotion of IQOS as a reduced-risk product has sparked debate with public health bodies like the U.S. Food and Drug Administration, which granted it a Modified Risk Tobacco Product authorization but with ongoing scrutiny. Allegations of targeting youth in markets like the Philippines have also drawn criticism from groups like the Campaign for Tobacco-Free Kids.

Corporate affairs

The company's leadership is under Jacek Olczak, who succeeded André Calantzopoulos as Chief Executive Officer. Its board of directors includes figures like Luis Cantarell and Shlomo Yanai. A major strategic shift was announced with its ambition to eventually stop selling cigarettes, focusing its resources on smoke-free products. This transformation is central to its environmental, social, and governance (ESG) reporting and its stated support for the WHO Framework Convention on Tobacco Control. The company is a constituent of the S&P 500 index and its major shareholders include institutional investors like The Vanguard Group and BlackRock.

Category:Tobacco companies of the United States Category:Companies listed on the New York Stock Exchange